<DOC>
	<DOCNO>NCT02425501</DOCNO>
	<brief_summary>The objective study investigate safety effectiveness EYLEA</brief_summary>
	<brief_title>Special Drug Use Investigation EYLEA Diabetic Macular Edema</brief_title>
	<detailed_description>This prospective , non-interventional , multi center post-authorization safety study include patient diagnosis myopic choroidal neovascularization . The investigator make choice treatment ( EYLEA ) well decision use EYLEA accord Japanese Package Insert prior enrol patient study . The observation period patient start therapy EYLEA initiate . The enrollment period 2 year . Patients follow time period 2 year longer possible ( e.g . lose follow-up ) within 2 year . In total , 600 patient recruit . For patient , data collect defined electronic case report form ( eCRF ) initial visit , follow-up visit final visit , either routine clinical visit ( per investigator routine practice ) .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>Patients start EYLEA treatment Diabetic Macular Edema ( DME ) Patients already receive EYLEA treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Aflibercept</keyword>
	<keyword>anti-VEGF</keyword>
</DOC>